Sugi Predict

Sugi Predict / Compounds / SCHEMBL3205538

SCHEMBL3205538

SCHEMBL3205538

Cn1ccc(NC(=O)Nc2cc(CN3CCN(C(=O)O)CC3)ccc2F)n1

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.47
▸ MAPT P10636 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ FAAH O00519 5/20 0.44
▸ CHRNA7 P36544 1/20 0.41
▸ CCR3 P51677 4/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ IDH2 P48735 1/20 0.40
▸ RAF1 P04049 1/20 0.39
▸ CHEK1 O14757 1/20 0.39
▸ PARP1 P09874 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL401111 0.91 NPC1 (0.46) NPC1MAPTRAB9ASMN1; SMN2FAAH
SCHEMBL3189482 0.82 ALK (0.47) NPC1MAPTRAB9ASMN1; SMN2FAAH
SCHEMBL3214359 0.81 FAAH (0.49) NPC1RAB9ASMN1; SMN2FAAHCCR3
SCHEMBL3214089 0.79 CHRNA7 (0.46) NPC1MAPTRAB9ASMN1; SMN2FAAH
SCHEMBL3201395 0.79 FAAH (0.47) NPC1RAB9AFAAHCCR3ALDH1A1
SCHEMBL3204614 0.78 FAAH (0.45) NPC1RAB9ASMN1; SMN2FAAHCHRNA7
SCHEMBL3191265 0.78 FAAH (0.43) SMN1; SMN2FAAHCHRNA7CCR3ALDH1A1
SCHEMBL3198483 0.77 FAAH (0.45) NPC1RAB9AFAAHCCR3ALDH1A1
SCHEMBL3209334 0.77 FAAH (0.43) SMN1; SMN2FAAHCHRNA7CCR3ALDH1A1
SCHEMBL3200392 0.77 FAAH (0.44) SMN1; SMN2FAAHCCR3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2022-06-16 — — US disclosed
US-10975034-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2021-04-13 — — US disclosed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US disclosed
US-10385023-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2019-08-20 — — US disclosed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US disclosed
US-10035770-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED (US) 2018-07-31 — — US disclosed
US-20170267638-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2017-09-21 — — US disclosed
US-9643925-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED 2017-05-09 — — US disclosed
US-20160115133-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2016-04-28 — — US disclosed
US-9150564-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2015-10-06 — — US disclosed
US-20120172372-A1 Ureas and Their Use in the Treatment of Heart Failure CYTOKINETICS, INC. 2012-07-05 — — US disclosed
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2010-02-04 — — US disclosed
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2009-10-01 — — US disclosed
US-20090099198-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-04-16 — — US disclosed
US-7507735-B2 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INC. (US) 2009-03-24 — — US disclosed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US disclosed
US-20070208000-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-09-06 — — US disclosed
US-20070197505-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-08-23 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172372-A1 Ureas and Their Use in the Treatment of Heart Failure TNNI3, TNNT2, MYLK2 NPC1 4481/4885MAPT 449/4885RAB9A 2950/4885
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 NPC1 4691/4885MAPT 900/4885RAB9A 3170/4885
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate TNNI3, MYLK2, TNNT2 NPC1 4804/4885MAPT 1075/4885RAB9A 2091/4885
US-20170267638-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 NPC1 4608/4885MAPT 663/4885RAB9A 2773/4885
US-10385023-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 NPC1 4608/4885MAPT 663/4885RAB9A 2773/4885
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 NPC1 4608/4885MAPT 663/4885RAB9A 2773/4885
US-20090099198-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 NPC1 4608/4885MAPT 663/4885RAB9A 2773/4885
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 NPC1 4608/4885MAPT 663/4885RAB9A 2773/4885
US-20070208000-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 NPC1 4691/4885MAPT 900/4885RAB9A 3170/4885
US-20070197505-A1 Certain chemical entities, compositions and methods TNNC1, TNNI3, TNNT2 NPC1 4826/4885MAPT 49/4885RAB9A 3510/4885
US-20160115133-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 NPC1 4608/4885MAPT 663/4885RAB9A 2773/4885
US-10975034-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 NPC1 4608/4885MAPT 663/4885RAB9A 2773/4885
US-10035770-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 NPC1 4608/4885MAPT 663/4885RAB9A 2773/4885
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods TNNI3, TNNT2, MYLK2 NPC1 4691/4885MAPT 900/4885RAB9A 3170/4885
US-20090036447-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 NPC1 4608/4885MAPT 663/4885RAB9A 2773/4885
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 NPC1 4608/4885MAPT 663/4885RAB9A 2773/4885
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods TNNC1, TNNI3, TNNT2 NPC1 4826/4885MAPT 49/4885RAB9A 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.